Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples
Timothy A. Bates, Hans C. Leier, Zoë L. Lyski, James R. Goodman, Marcel E. Curlin, William B. Messer, Fikadu Tafesse
Abstract
Vaccination with 2 doses of the BNT162b2 vaccine (Pfizer-BioNTech) reportedly provides 95% protection from COVID-19. 1 However, patient age is known to contribute to the risk of
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Neutralization2019-20 coronavirus outbreakVaccinationImmune systemVirologyImmunologyAntibodyInternal medicineDiseaseOutbreakInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19